Get the Stockscreener App
10.14
5.08%
0.49
Nurix Therapeutics Inc stock is traded at $10.14, with a volume of 617.55K.
It is up +5.08% in the last 24 hours and down -9.87% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$9.65
Open:
$9.77
24h Volume:
617.55K
Relative Volume:
0.74
Market Cap:
$775.20M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.5087
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-4.16%
1M Performance:
-9.87%
6M Performance:
-39.89%
1Y Performance:
-56.07%
1-Day Range:
$9.6351
$10.33
1-Week Range:
$9.29
$10.68
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
10.14 | 780.17M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4.4%Time to Sell? - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.7% HigherWhat's Next? - MarketBeat
Deutsche Bank AG Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Will Volume Confirm Reversal in Nurix Therapeutics Inc.July 2025 Intraday Action & High Accuracy Swing Trade Signals - newsimpact.co.kr
What technical models suggest about Nurix Therapeutics Inc.’s comebackJuly 2025 Recap & Growth Focused Stock Reports - Newser
Market reaction to Nurix Therapeutics Inc.’s recent news2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Is Nurix Therapeutics Inc. stock reversal real or fakeEarnings Overview Report & Low Drawdown Trading Techniques - Newser
Nurix Therapeutics Inc. Stock Support and Resistance Levels You Should Know2025 Short Interest & Reliable Momentum Entry Alerts - Newser
Technical Bounce Expected in Nurix Therapeutics Inc. Next Week2025 Institutional Moves & Comprehensive Market Scan Reports - metal.it
Is Nurix Therapeutics Inc. trending in predictive chart modelsJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
What to do if you’re stuck in Nurix Therapeutics Inc.Earnings Trend Report & Long Hold Capital Preservation Plans - Newser
Analyzing Nurix Therapeutics Inc. with multi timeframe charts2025 Stock Rankings & Safe Entry Trade Reports - Newser
Technical signs of recovery in Nurix Therapeutics Inc.Weekly Volume Report & Daily Price Action Insights - Newser
Nurix Therapeutics Inc. stock trend outlook and recovery pathFed Meeting & Daily Growth Stock Tips - Newser
Is Nurix Therapeutics Inc. stock ready for a breakoutJuly 2025 Momentum & Fast Entry High Yield Stock Tips - Newser
How sentiment analysis helps forecast Nurix Therapeutics Inc.2025 Institutional Moves & Fast Exit and Entry Trade Guides - Newser
Nurix Therapeutics Inc. stock retracement – recovery analysis2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
Automated trading signals detected on Nurix Therapeutics Inc.CEO Change & Verified Short-Term Plans - Newser
Using fundamentals and technicals on Nurix Therapeutics Inc.Market Volume Summary & Community Consensus Stock Picks - Newser
Is Nurix Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
How Nurix Therapeutics Inc. stock performs during market volatilityPortfolio Performance Summary & Low Risk Entry Point Guides - Newser
Sector ETF performance correlation with Nurix Therapeutics Inc.Weekly Trade Recap & High Return Trade Opportunity Guides - Newser
Does Nurix Therapeutics Inc. stock pay reliable dividendsPortfolio Gains Report & Accurate Buy Signal Notifications - Newser
Trend analysis for Nurix Therapeutics Inc. this weekJuly 2025 Highlights & Reliable Entry Point Trade Alerts - Newser
Real time scanner hits for Nurix Therapeutics Inc. explainedEntry Point & Low Risk Entry Point Tips - Newser
Can Nurix Therapeutics Inc. Escape Recent Bear ChannelInvestment Strategy Designed for Capital Protection - beatles.ru
Risks Still Elevated At These Prices As Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Dive 25% - 富途牛牛
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Victory Capital Management Inc. Has $352,000 Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,402 Shares - MarketBeat
Equity Inducement as a Growth Engine: How Nurix Therapeutics Aligns Talent and Shareholder Value in Biotech Innovation - AInvest
What makes Nurix Therapeutics Inc. stock price move sharplyGet exclusive market analysis for investors - Jammu Links News
Is Nurix Therapeutics Inc. stock overvalued or undervaluedUnstoppable investment returns - Jammu Links News
Nurix Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Jammu Links News
Why is Nurix Therapeutics Inc. stock attracting strong analyst attentionHigh-yield portfolio picks - Jammu Links News
How many analysts rate Nurix Therapeutics Inc. as a “Buy”Access high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Nurix Therapeutics Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - Jammu Links News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $51,739.08 in Stock - MarketBeat
What is Nurix Therapeutics Inc. company’s growth strategyCapitalize on emerging investment opportunities - Jammu Links News
What are Nurix Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals for profits - Jammu Links News
Is it the right time to buy Nurix Therapeutics Inc. stockDiscover high-impact investment opportunities - Jammu Links News
Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) PT at $29.31 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.9%Time to Buy? - MarketBeat
When is Nurix Therapeutics Inc. stock expected to show significant growthAdvanced Screener Data Feed To Watch Now - Jammu Links News
Nurix Therapeutics CFO Hans van Houte sells 5402 shares at $11.03 per share. - AInvest
Oppenheimer Reiterates "Outperform" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Y Intercept Hong Kong Ltd Buys Shares of 31,458 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):